Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viva Biotech HoldingsFRA:VB0 +0.70%47 Cash Ratio is 0.77 as of Dec. 2025, which is 9% below its 10-year median of 0.85. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,384 Biotechnology companies, Viva Biotech Holdings ranks worse than 77.38% on this metric.
Viva Biotech Holdings has a Cash Ratio of 0.77. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Viva Biotech Holdings's Cash Ratio or its related term are showing as below:
FRA:VB0'
s Cash Ratio Range Over the Past 10 Years
Min: 0.25 Med: 0.85 Max: 12.8
Current: 0.77
During the past 10 years, Viva Biotech Holdings's highest Cash Ratio was 12.80. The lowest was 0.25. And the median was 0.85.
FRA:VB0's Cash Ratio is ranked worse than 77.38% of 1384
companies
in the Biotechnology industry
Industry Median: 2.94
vs FRA:VB0: 0.77
Viva Biotech Holdings (FRA:VB0) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Cash Ratio of 0.77 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Viva Biotech Holdings and its competitors. This is near median its historical median of 0.85. Over the past decade, Viva Biotech Holdings' Cash Ratio has ranged from 0.25 to 12.80. According to the industry distribution chart, Viva Biotech Holdings ranks #1071 out of 1384 companies in the Biotechnology industry, placing it in the top 77.4%.
Is Viva Biotech Holdings' Cash Ratio too high?
Viva Biotech Holdings' current Cash Ratio of 0.77 is near median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 12.80. The Biotechnology industry median Cash Ratio is 2.94. Viva Biotech Holdings' value of 0.77 is 73.8% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #1071 out of 1384 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #1071 out of 1384 companies for Cash Ratio. This places Viva Biotech Holdings in the lower half of its industry. The industry median Cash Ratio is 2.94. Viva Biotech Holdings' value of 0.77 is 73.8% below this benchmark. Historically, Viva Biotech Holdings' own Cash Ratio has ranged from 0.25 to 12.80 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 2.94, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Cash Ratio of 0.77 is 73.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Cash Ratio is 0.77, which is near median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.14 — trading 80% above its estimated fair value. The current Cash Ratio is 0.77, which is near median its 10-year median of 0.85 and 73.8% below the Biotechnology industry median of 2.94. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Cash Ratio is 0.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.14 is trading 80% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Cash Ratio: 0.77 (near median its 10-year median of 0.85)
GF Value™: €0.08 vs. price of €0.14 (80% above fair value)
Industry Position: 73.8% below the Biotechnology median (#1071 of 1384)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
